Document is current
Any future updates will be listed below
-
Authors
Nicolò, Massimo https://orcid.org/0000-0002-7824-3091
Ciucci, Francesco
Nardi, Marco
Parolini, Barbara
Russo, Andrea
Scupola, Andrea
Torregrossa, Salvatore
Vadalà, Maria
,
-
Funding
Funding for this research was provided by:
Bayer S.p.A, Milan, Italy
Università degli Studi di Genova
- License Information
-
More Information
Article History
Received: 10 December 2021
Revised: 30 March 2022
Accepted: 15 April 2022
First Online: 5 May 2022
Change Date: 28 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and the guidelines of the European Medicines Agency and the International Council for Harmonization Guideline E3: Good Clinical Practice. The protocol and any amendments were reviewed and approved by each study site’s Independent Ethics Committee or Institutional Review Board before the start of the study.
: All patients provided written informed consent for participation in this study.
: Not applicable.
: MV received consulting fees from Bayer Italia S.p.A., Novartis Italia S.p.A, and Allergan Italia S.p.A. outside the scope of the submitted work. The remaining authors have no competing interests to declare.
